Tiotropium
From Pharmacopedia
More actions
Tiotropium
Spiriva, Spiriva Respimat
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
18 mcg DPI once daily (HandiHaler); 2.5 mcg per actuation × 2 inhalations once daily (Respimat)
Preparations
18 mcg HandiHaler capsules; 2.5 mcg/actuation Respimat solution inhaler (1.25 mcg/actuation for asthma indication)
US FDA Max
One dose per day
Pharmacology
Routes
Inhaled (DPI, soft-mist inhaler)
Onset
Bronchodilation 30 minutes; steady-state at 1-2 weeks
Duration
24 hours (long receptor dissociation half-life from M3)
Half-life
~25-44 hours plasma; receptor kinetics drive the once-daily duration[1]
Bioavailability
Inhaled lung deposition ~20%; systemic absorption from lung ~33%; oral component negligible[1]
Pregnancy
Limited data; LABA/LAMA strategies in pregnancy generally favor agents with the most reassuring data.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Tiotropium is a long-acting muscarinic antagonist binding M1/M2/M3 receptors with markedly slower dissociation from M3 (the airway-relevant subtype) than from M2, producing functional M3 selectivity and 24-hour bronchodilation from once-daily dosing.0 Class adverse effects are anticholinergic in nature (dry mouth, urinary retention, blurred vision, constipation), though systemic absorption from inhaled administration is low. Use with caution in narrow-angle glaucoma and bladder-outlet obstruction[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Spiriva HandiHaler (tiotropium bromide), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021395s060lbl.pdf